Vir's CMO says he's surprised that a low dose of their hepatitis B drug appears promising in early slice of data — shares soar
Initial topline data from a Phase I study of a new therapeutic for chronic hepatitis B virus was so promising that it surprised even the CMO of the company that produces it.
Vir Biotechnology on Tuesday announced that its VIR-3434 molecule reduced the level of virus surface antigens present in a blinded patient cohort after eight days of the trial with just a single 6 mg dose. Six of the eight patients in the cohort were given the molecule, and the other two a placebo—all six who received the molecule saw a mean antigen reduction of 1.3 log10 IU/mL, Vir said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.